Our news

• NovaMedica appoints Yulia Sobakina as Commerce & Marketing Vice President

  02 November 2017

  

  Yulia Sobakina, who used to head Department of private label brands in the pharmacy chain Rigla of the Protek Group of Companies, has been appointed as Commerce & Marketing Vice President of the pharmaceutical company NovaMedica. 

• NovaMedica appoints Rustam Iksanov as R&D Vice President

  11 August 2017

  

  Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.

• NovaMedica began construction of a pharmaceutical plant in the Kaluga region

  30 May 2017

  

  Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

• NovaMedica appoints Alexander Kuzin as General Director (CEO)

  29 May 2017

  

  Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the appointment of Alexander Kuzin to the post of General Director (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017.

• NovaMedica and Pfizer won the “Platinum Ounce” award in the nomination “Deal of the Year”

  21 April 2017

  

  NovaMedica, Russian pharmaceutical company, and Pfizer, one of the leaders of the world biopharmaceutical industry, were recognized as winners of the open professional contest “Platinum Ounce” in the nomination “Deal of the Year” for the long-term partnership agreement which envisages construction of a high-technology pharmaceutical production facility and localization of more than 30 life-saving and essential drugs in Russia. 

• NovaMedica launched Technology Center to develop innovative drugs

  19 April 2017

  

  NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

• Raikhana Shangareyeva becomes Vice President, Production, at NovaMedica

  17 February 2017

  

  Raikhana Shangareyeva, who was previously in charge of manufacturing at an enterprise of JSC R-Pharm, has been appointed Vice President, Production, of the pharmaceutical company NovaMedica. She will be trusted with making NovaMedica’s production facility operational and with organizing workflow processes there.

• Happy New Year!

  30 December 2016

  

  Merry Christmas and a prosperous New Year!  Best wishes for 2017!

• Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

  23 December 2016

  

  Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

• NovaMedica prepares to launch the new drug development laboratories

  10 November 2016

  

  Russian pharmaceutical company NovaMedica launches R&D laboratories as part of its Technology Center project for the development and pilot production of innovative drugs. The facilities are designed to address the most challenging scientific tasks based on the state-of-the-art platforms incorporating nanotechnologies. The project investment totals $15m.